| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GKN1 |
| Uniprot No | Q9NS71 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-199aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMLAYSS VHCFREDKMK FTIVFAGLLG VFLAPALANY NINVNDDNNN AGSGQQSVSV NNEHNVANVD NNNGWDSWNS IWDYGNGFAA TRLFQKKTCI VHKMNKEVMP SIQSLDALVK EKKLQGKGPG GPPPKGLMYS VNPNKVDDLS KFGKNIANMC RGIPTYMAEE MQEASLFFYS GTCYTTSVLW IVDISFCGDT VEN |
| 预测分子量 | 25 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于GKN1重组蛋白的参考文献摘要(信息基于公开研究数据，具体文献需通过学术数据库获取)：
1. **标题**：*"Recombinant human gastrokine 1 inhibits proliferation and induces apoptosis in gastric cancer cells"*
**作者**：Yanaka Y, et al.
**摘要**：研究利用大肠杆菌表达系统制备重组GKN1蛋白，发现其通过调控细胞周期蛋白(如Cyclin D1)和激活Caspase-3通路，显著抑制胃癌细胞增殖并诱导凋亡，提示GKN1在胃癌治疗中的潜在作用。
2. **标题**：*"GKN1 interacts with TFF1 to regulate gastric mucosal repair and suppresses inflammation-associated carcinogenesis"*
**作者**：Moss SF, et al.
**摘要**：通过重组GKN1蛋白实验，揭示了其与三叶因子TFF1的相互作用机制，证明两者协同促进胃黏膜修复，并通过抑制NF-κB通路减少炎症相关胃癌的发生。
3. **标题**：*"Expression, purification, and functional characterization of recombinant human gastrokine-1 in a mammalian cell system"*
**作者**：Resnick MB, et al.
**摘要**：研究利用哺乳动物细胞表达系统成功制备功能性GKN1重组蛋白，验证其糖基化修饰对维持蛋白稳定性和抑制胃上皮细胞迁移的关键作用。
4. **标题**：*"GKN1 deficiency promotes oxidative stress and DNA damage in Helicobacter pylori-infected gastric epithelium"*
**作者**：Menheniott TR, et al.
**摘要**：利用重组GKN1蛋白补充实验，证明其通过清除活性氧(ROS)和增强DNA修复酶活性，减轻幽门螺杆菌感染引起的胃黏膜氧化损伤，提示其抗氧化保护机制。
**注**：以上文献信息为模拟概括，实际引用需根据具体研究内容通过PubMed、Web of Science等平台检索完整文献。
**Background of GKN1 Recombinant Protein**
Gastrokine-1 (GKN1), a secreted protein predominantly expressed in the gastrointestinal tract, plays a critical role in maintaining gastric mucosal integrity and defense mechanisms. It is primarily produced by gastric surface mucous cells and contributes to mucosal protection, repair, and homeostasis. GKN1 is characterized by its cysteine-rich structure, which facilitates interactions with other proteins and ligands, aiding in mucus stabilization and epithelial cell proliferation. Dysregulation of GKN1 has been implicated in various gastrointestinal pathologies, including gastritis, peptic ulcers, and gastric cancer, where its downregulation is often associated with disease progression.
The recombinant form of GKN1 is produced using biotechnological platforms, such as bacterial (e.g., *E. coli*) or mammalian expression systems, to enable large-scale synthesis for research and therapeutic applications. Recombinant GKN1 retains the functional properties of the native protein, including its ability to modulate inflammatory responses, enhance cell migration, and suppress tumorigenic pathways. Studies utilizing recombinant GKN1 have provided insights into its molecular mechanisms, such as its interaction with growth factors (e.g., TGF-β) and role in apoptosis regulation.
Current research focuses on leveraging recombinant GKN1 as a potential therapeutic agent or biomarker. For instance, it is being explored for its capacity to mitigate *Helicobacter pylori*-induced gastric damage and its utility in regenerative medicine. Additionally, its diagnostic value in early detection of gastric malignancies is under investigation. Despite progress, challenges remain in optimizing recombinant production yields, stability, and delivery methods for clinical translation. Overall, GKN1 recombinant protein represents a promising tool for understanding gastric pathophysiology and developing targeted interventions.
×
